Posted by Michael Wonder on 14 Sep 2021
Alnylam submits marketing authorisation application to the European Medicines Agency for investigational vutrisiran for the treatment of hereditary ATTR amyloidosis with polyneuropathy
13 September 2021 - If approved, vutrisiran will provide a new, subcutaneously administered, once quarterly treatment option for patients with hATTR amyloidosis.
Alnylam Pharmaceuticals today announced the submission of a marketing authorisation application to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin mediated amyloidosis in adult patients with polyneuropathy.
